Indian Healtcare firm gets USFDA nod for Symmetrel’s generic version – Feedback

Drug firm Jubilant Life SciencesBSE -2.21 % today said its subsidiary has received final approval from the US health regulator for Amantadine Hydrochloride tablets, an anti-viral and anti-Parkinsons drug.

Approved drug, generic version of Symmetrel of Endo, is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. It is also indicated in the treatment of Parkinsonism and drug-induced extrapyramidal reactions. “Jubilant Pharma Ltd, a material wholly owned subsidiary of the company, through one of its wholly owned subsidiaries, has received abbreviated new drug application (ANDA) final approval for Amantadine Hydrochloride tablets, 100 mg,”.

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *